Continuity Biosciences, LLC announced a strategic investment in PinPrint, Inc., a company specializing in high-resolution 3D-printed microneedle technology. This move marks Continuity's expansion beyond therapeutic delivery into aesthetic and cosmetic applications, significantly broadening its market reach and technological capabilities.
PinPrint's innovative technology was developed by Joseph DeSimone, PhD, the Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering at Stanford University. The breakthrough platform eliminates resin over-curing in negative spaces, enabling the construction of ultra-precise microchannels and voids critical for applications such as microneedle patches and microfluidic devices.
"By integrating high-resolution 3D printing with advanced drug delivery, we're redefining the patient experience across therapeutic and cosmetic categories—offering a new standard for precision, personalization, and comfort," said Dr. DeSimone, highlighting the transformative potential of the technology.
Revolutionary Microneedle Patch Technology
PinPrint's flagship innovation is a next-generation microneedle patch designed to deliver vaccines and active agents intradermally. This technology aims to replace traditional injections, potentially transforming how medications and cosmetic compounds are administered.
The microneedle platform represents a significant advancement in drug delivery systems, particularly for dermatological applications. By enabling direct intradermal delivery, the technology may improve efficacy while reducing discomfort associated with conventional injection methods.
Strategic Alignment with Continuity's Mission
For Continuity Biosciences, this investment aligns with its core mission of advancing targeted delivery technologies. The company has been developing implanted nanofluidic platforms through collaboration with the Grattoni Lab at Houston Methodist Hospital, focusing on extended, zero-order release capabilities.
"This investment allows us to expand from implanted nanofluidic systems to a non-implanted microfluidic platform," explained Ramakrishna Venugopalan, PhD, Co-Founder and CEO of Continuity Biosciences. "It opens the door for more effective delivery of dermatologic, aesthetic, and cosmetic agents directly into the dermis."
The strategic move positions Continuity to address a broader range of medical and cosmetic needs, potentially accelerating the company's growth in the rapidly expanding aesthetics market.
Leadership Integration and Future Directions
As part of the transaction, Dr. Venugopalan will join PinPrint's Board of Directors, bringing his expertise in drug delivery systems to guide the company's strategic direction.
"We welcome Krishna to the Board," said Renee Ryan, MBA, Co-Founder and CEO of PinPrint, Inc. "His domain expertise and strategic leadership will be instrumental as we redefine what's possible in drug and vaccine delivery."
This collaboration between Continuity Biosciences and PinPrint represents a significant step forward in addressing unmet needs in both therapeutic and cosmetic drug delivery. The integration of high-precision 3D printing with advanced delivery systems could potentially transform patient experiences across multiple treatment categories.
The investment comes at a time when demand for minimally invasive drug delivery systems is growing, particularly in the aesthetics and dermatology sectors. By combining their technological expertise, the two companies aim to accelerate innovation in this rapidly evolving field.
Market Implications and Clinical Potential
The aesthetic medicine market has seen substantial growth in recent years, with increasing demand for minimally invasive procedures and advanced delivery systems for cosmetic compounds. PinPrint's technology could potentially address key challenges in this sector, including precision of delivery, patient comfort, and treatment efficacy.
For therapeutic applications, the microneedle technology offers potential advantages for vaccine delivery and administration of medications requiring precise dosing. The ability to deliver compounds directly to the dermis could improve bioavailability for certain drugs while reducing systemic exposure.
The partnership between Continuity Biosciences and PinPrint highlights the growing convergence between medical technology and aesthetic applications, a trend that continues to reshape the pharmaceutical and cosmetic industries.
